Polar Capital Biotech S Inc (GBP) |
Performance History | 30/04/2024 |
Growth of 1,000 (EUR) |
Fund | 29.4 | 12.9 | -0.7 | 12.6 | 2.6 | |
+/-Cat | 10.2 | 15.9 | 12.1 | 11.5 | 4.9 | |
+/-Idx | 3.6 | 6.0 | 2.3 | 2.7 | -5.5 | |
Category: Sector Equity Biotechnology | ||||||
Benchmarks: Morningstar Gbl Biotechnolo... |
Key Stats | ||
NAV 02/05/2024 | GBP 37.59 | |
Day Change | 1.46% | |
Morningstar Category™ | Sector Equity Biotechnology | |
ISIN | IE00BF23BW06 | |
Fund Size (Mil) 01/05/2024 | USD 1670.82 | |
Share Class Size (Mil) 01/05/2024 | USD 14.65 | |
Max Initial Charge | 5.00% | |
Ongoing Charge 31/12/2023 | 0.87% |
Investment Objective: Polar Capital Biotech S Inc (GBP) |
The investment objective of the Fund is to preserve capital and achieve long term capital appreciation. |
Returns | ||||||||||||||||
|
Management | ||
Manager Name Start Date | ||
David Pinniger 31/10/2013 | ||
Gareth Powell 31/10/2013 | ||
Inception Date 31/10/2013 |
Advertisement |
Benchmarks | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology NR USD | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Polar Capital Biotech S Inc (GBP) | 31/03/2024 |
|
|
Top 5 Holdings | Sector | % |
Regeneron Pharmaceuticals Inc | Healthcare | 6.38 |
Amgen Inc | Healthcare | 5.50 |
argenx SE | Healthcare | 4.92 |
Blueprint Medicines Corp | Healthcare | 4.33 |
Zealand Pharma A/S | Healthcare | 4.09 |
Increase Decrease New since last portfolio | ||
Polar Capital Biotech S Inc (GBP) |